13F Holdings
中文EN

QGEN QIAGEN N.V.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1015820 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.7%
TTM net income YoY408.3%
TTM EPS YoY424.3%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR0.1%

Margins

Gross margin62.2%
Operating margin22.3%
Net margin20.3%
FCF margin21.7%
EBITDA margin31.6%

Returns

ROE11.6%
ROA7.1%
ROIC (approx.)9.1%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets39.9%
Debt / equity0.44x
Current ratio3.90x
Interest coverage14.01x

Cash quality & payout

Operating cash flow / net income1.54x
Accruals ratio-3.8%
Payout ratio12.8%
Capex / revenue9.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B
Cost of revenue$790.50M$1.01B$731.62M$756.96M$800.84M
Gross profit$1.30B$967.35M$1.23B$1.38B$1.45B
R&D expense$187.52M$193.49M$198.51M$189.86M$189.96M
SG&A expense$125.68M$113.43M$119.25M$129.72M$128.08M
Operating income$465.85M$97.71M$409.94M$531.46M$630.08M
Interest expense$33.26M$43.84M$53.41M$58.36M$54.48M
Pretax income$490.26M$121.15M$429.81M$512.60M$625.83M
Income tax$65.39M$37.56M$88.51M$89.39M$113.23M
Net income$424.88M$83.59M$341.30M$423.21M$512.60M
EBITDA$659.60M$300.98M$615.27M$739.86M$845.01M
EPS (basic)1.960.381.501.862.25
EPS (diluted)1.940.371.481.842.21
Dividends declared per share0.25————
Weighted avg. shares (diluted)218.88M224.72M230.62M230.14M232.03M
Balance sheet
Cash & equivalents$839.00M$663.55M$668.08M$730.67M$880.52M
Short-term investments$259.91M$489.44M$389.70M$687.60M$184.78M
Receivables$402.61M$349.28M$381.88M$323.75M$362.13M
Inventory$301.89M$279.26M$398.38M$357.96M$327.52M
Current assets$2.00B$1.96B$2.15B$2.39B$2.11B
PP&E, net$923.95M$753.61M$765.04M$662.17M$638.18M
Goodwill$2.70B$2.43B$2.48B$2.35B$2.35B
Intangibles$386.43M$303.81M$526.82M$544.80M$627.44M
Total assets$6.28B$5.69B$6.12B$6.29B$6.15B
Current liabilities$512.14M$1.04B$1.08B$974.52M$1.52B
Short-term debt$0$551.88M$587.97M$389.55M$847.63M
Long-term debt$1.65B$839.66M$921.82M$1.47B$1.09B
Total debt$1.65B$1.39B$1.51B$1.86B$1.94B
Total liabilities$2.50B$2.12B$2.31B$2.82B$3.05B
Shareholders' equity$3.78B$3.57B$3.81B$3.47B$3.10B
Net debt$815.42M$727.99M$841.71M$1.13B$1.06B
Cash flow statement
Operating cash flow$654.33M$673.55M$459.45M$715.26M$639.00M
Capital expenditure$201.05M$167.17M$149.71M$129.22M$189.90M
Free cash flow$453.28M$506.38M$309.75M$586.04M$449.10M
Investing cash flow-$305.28M-$249.23M-$87.66M-$726.76M-$202.43M
Financing cash flow-$178.98M-$422.90M-$433.83M-$125.80M-$150.37M
Depreciation & amortization$193.75M$203.27M$205.34M$208.40M$214.93M
Stock-based compensation$50.40M$43.63M$47.10M$49.51M$38.39M
Dividends paid$54.24M$0$0——
Share buybacks$280.09M$292.10M$0$0$99.99M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.